Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: A potential mechanism of apoptotic epithelial turnover

Diseases of the Esophagus

Volumn 12, Issue 2, 1999, Pages 90-98

  Bennett, M W ^a   O'Connell, J ^a   O'Sullivan, G C ^a   Roche, D ^a   Brady, C ^a   Collins, J K ^a   Shanahan, F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

Apoptosis; Epithelium; Esophagus; Fas ligand; Fas receptor; Homeostasis; Immunohistochemistry; In situ hybridization

Indexed keywords

CD45 ANTIGEN; CELL SURFACE RECEPTOR; FAS LIGAND; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; EPITHELIUM CELL; ESOPHAGUS MUCOSA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOCYTE; PRIORITY JOURNAL; SQUAMOUS CELL;

ANTIGENS, CD45; ANTIGENS, CD95; APOPTOSIS; EPITHELIAL CELLS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FAS LIGAND PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER;

EID: 0032776616     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.1999.00032.x     Document Type: Article

References (32)

1. Katada N, Hinder R A, Smyrk T C et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997; 132: 728-733.
2. DeNardi F G, Riddell R H. The normal esophagus. Am J Surg Pathol 1991; 15: 296-309.
3. Lynch D H, Ramsdell F, Alderson M R. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
4. Berthou C, Michel M, Soulie A et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997; 159: 5293-5300.
5. Sanberg P R, Saporta S, Borlongan C V, Othberg A I, Allen R C, Cameron D F. The testis-derived cultured Sertoli cell as a natural Fas-L secreting cell for immunosuppressive cellular therapy. Cell Transplant 1997; 6: 191-193.
6. Griffith T S, Brunner T, Fletcher S M, Green D R, Ferguson T A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 17: 1189-1192.
7. Runic R, Lockwood C J, Ma Y, Dipasquale B, Guller S Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab 1996; 81: 3119-3122.
8. Saas P, Walker P R, Hahne M et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
9. French L E, Hahne M, Viard I et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immuneprivileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-343.
10. Suzuki A, Enari M, Eguchi Y, Matsuzawa A, Nagata S, Tsujimoto Y, Iguchi T. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J 1996; 15: 211-215.
11. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet 1995; 11: 294-300.
12. Lee J, Richburg J H, Younkin S C, Boekelheide K. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 1997; 138: 2081-2088.
13. O'Connell J, O'Sullivan G C, Collins J K, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
14. Shiraki K, Tsuji N, Shioda T, Isselbacher K J, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-6425.
15. Niehans G A, Brunner T, Frizelle S P et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
16. Strand S, Hofmann W J, Hug H et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 2: 1361-1366.
17. Galle P R, Hofmann W J, Walczak H et al. Involvement of the CD95 (Apo-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223-1230.
18. Charriaut-Marlangue C, Ben-Ari Y. A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 1995; 7: 61-64.
19. Griffith T S, Ferguson T A. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240-244.
20. McCall C A, Cohen J J. Programmed cell death in terminally differentiating keratinocytes: role of endogenous endonuclease. J Invest Dermatol 1991; 97: 111-114.
21. Birchall M A, Winterford C M, Allan D J, Harmon B V. Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Eur J Cancer B Oral Oncol 1995; 31B: 380-383.
22. Polakowska R R, Piacentini M, Bartlett R, Goldsmith L A, Haake A R. Apoptosis in human skin development: morphogenesis, periderm, and stem cells. Dev Dyn 1994; 199: 176-.
23. Sarbia M, Bittinger F, Porschen R et al. Bc1-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 1996; 69: 324-328.
24. Jordan R C, Catzavelos G C, Barrett A W, Speight P M. Differential expression of bc1-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 1996; 32B: 394-400.
25. Verhaegh M E, Sanders C J, Arends J W, Neumann H A. Expression of the apoptosis-suppressing protein Bc1-2 in nonmelanoma skin cancer. Br J Dermatol 1995; 132: 740-744.
26. Krajewski S, Krajewska M, Reed J C. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bc1-2 protein family. Cancer Res 1996; 56: 2849-2285.
27. Dekker N P, Lozada-Nur F, Lagenaur L A, MacPhail L A, Bloom C Y, Regezi J A. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1997; 26: 170-175.
28. Cui H, Ju S T, Sherr D H. Functional expression of Fas (CD 1996; 95): protein in autoimmune lpr mice. Cell Immunol 174: 35-41.
29. Griffith T S, Yu X, Herndon J M, Green D R, Ferguson T. A CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996; 5: 7-16.
30. O'Connell J, Bennett M W, O'Sullivan G C, Collins J K, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300.
31. De Maria R, Boirivant M, Cifone M G et al. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J Clin Invest 1996; 97: 316-322.
32. Liles W C, Kiener P A, Ledbetter J A, Aruffo A, Klebanoff S J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184: 429-440.